News on Celsion from BioPortfolio.com http://www.BioPortfolio.com Consolidated Celsion news from BioPortfolio.com Wed, 10 Feb 2010 16:11:10 GMT en Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041849&HITNO=0&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041849&THISHREF=http://c.moreover.com/click/here.pl%3fz2539240046%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041849&HITNO=0&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041849&THISHREF=http://c.moreover.com/click/here.pl%3fz2539240046%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEarthtimes.org: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041764&HITNO=1&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041764&THISHREF=http://c.moreover.com/click/here.pl%3fz2539222862%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041764&HITNO=1&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041764&THISHREF=http://c.moreover.com/click/here.pl%3fz2539222862%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSys-Con Media: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042184&HITNO=2&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042184&THISHREF=http://c.moreover.com/click/here.pl%3fz2539343879%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042184&HITNO=2&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042184&THISHREF=http://c.moreover.com/click/here.pl%3fz2539343879%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042174&HITNO=3&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042174&THISHREF=http://c.moreover.com/click/here.pl%3fz2539341979%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042174&HITNO=3&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042174&THISHREF=http://c.moreover.com/click/here.pl%3fz2539341979%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042067&HITNO=4&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042067&THISHREF=http://c.moreover.com/click/here.pl%3fz2539298238%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042067&HITNO=4&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042067&THISHREF=http://c.moreover.com/click/here.pl%3fz2539298238%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042182&HITNO=5&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042182&THISHREF=http://c.moreover.com/click/here.pl%3fz2539342875%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042182&HITNO=5&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042182&THISHREF=http://c.moreover.com/click/here.pl%3fz2539342875%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comIndividual.com: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042547&HITNO=6&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042547&THISHREF=http://c.moreover.com/click/here.pl%3fz2539449880%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042547&HITNO=6&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042547&THISHREF=http://c.moreover.com/click/here.pl%3fz2539449880%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMemphis Business Journal: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042546&HITNO=7&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042546&THISHREF=http://c.moreover.com/click/here.pl%3fz2539449908%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042546&HITNO=7&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042546&THISHREF=http://c.moreover.com/click/here.pl%3fz2539449908%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBiz Journals: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042541&HITNO=8&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042541&THISHREF=http://c.moreover.com/click/here.pl%3fz2539448843%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042541&HITNO=8&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042541&THISHREF=http://c.moreover.com/click/here.pl%3fz2539448843%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comWichita Business Journal: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042498&HITNO=9&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042498&THISHREF=http://c.moreover.com/click/here.pl%3fz2539436798%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042498&HITNO=9&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042498&THISHREF=http://c.moreover.com/click/here.pl%3fz2539436798%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPortland Business Journal: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042491&HITNO=10&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042491&THISHREF=http://c.moreover.com/click/here.pl%3fz2539436184%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042491&HITNO=10&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042491&THISHREF=http://c.moreover.com/click/here.pl%3fz2539436184%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSan Francisco Business Times: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042431&HITNO=11&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042431&THISHREF=http://c.moreover.com/click/here.pl%3fz2539415614%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042431&HITNO=11&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042431&THISHREF=http://c.moreover.com/click/here.pl%3fz2539415614%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSacramento Business Journal: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042387&HITNO=12&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042387&THISHREF=http://c.moreover.com/click/here.pl%3fz2539411200%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042387&HITNO=12&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042387&THISHREF=http://c.moreover.com/click/here.pl%3fz2539411200%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTwin Cities Business Journal: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042348&HITNO=13&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042348&THISHREF=http://c.moreover.com/click/here.pl%3fz2539397409%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042348&HITNO=13&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042348&THISHREF=http://c.moreover.com/click/here.pl%3fz2539397409%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTradingMarkets: Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancerhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042147&HITNO=14&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042147&THISHREF=http://c.moreover.com/click/here.pl%3fz2539329065%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042147&HITNO=14&MSIZE=28&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Celsion&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042147&THISHREF=http://c.moreover.com/click/here.pl%3fz2539329065%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBaltimore Business Journal: